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Predictive Value of Initial PET-SUVmax in Patients with
Locally Advanced Esophageal and Gastroesophageal
Junction Adenocarcinoma
Nabil P. Rizk, MD, Laura Tang, MD, PhD, Prasad S. Adusumilli, MD, Manjit S. Bains, MD,
Timothy J. Akhurst, MD, David Ilson, MD, PhD, Karyn Goodman, MD, and Valerie W. Rusch, MD
Introduction: We have previously shown that in early clinical
stage esophageal adenocarcinoma, a positron emission tomogra-
phy standardized uptake values (PET SUVmax) of 4.5 is asso-
ciated with earlier pathologic stage and predicts better survival.
In this study, we analyze the impact of the pretreatment PET
SUVmax in patients with locally advanced esophageal adenocar-
cinoma who undergo preoperative chemoradiotherapy.
Methods: We performed a retrospective analysis, selecting pa-
tients with adenocarcinoma of the esophagus who had a pretreat-
ment PET scan and who received chemoradiotherapy before
esophagectomy. Data recorded included demographics, PET
SUVmax, treatment details, pathologic details, and survival data.
Comparison of categorical variables was done by 2 analysis,
continuous variables by t test, survival analysis by the Kaplan-
Meier method, and comparisons of survival using the log-rank
test.
Results: Between January 1996 and September 2007, 189 patients
were appropriate for this analysis. The initial PET SUVmax was
4.5 in 28 patients and 4.5 in 161 patients. The two groups
were similar with regards to demographics and treatment details.
Patients in the low SUV group were less likely to show evidence
of treatment response after chemoradiotherapy, including a
higher likelihood of residual nodal disease and a lower likelihood
of a pathologic complete response and estimated treatment re-
sponse. However, both groups had similar survival.
Conclusions: Although the initial PET SUVmax does not predict
survival in patients with locally advanced esophageal adenocar-
cinoma who receive preoperative chemoradiotherapy, patients
with a high initial SUVmax respond better to preoperative therapy.
These results can be used to better select esophageal cancer
patients for combined modality treatment.
Key Words: Esophagus adenocarcinoma, PET scan, Preoperative
chemoradiotherapy.
(J Thorac Oncol. 2009;4: 875–879)
Positron emission tomography (PET) using [18F]-fluoro-deoxyglucose is commonly used in the workup of
patients with esophageal cancer. The most established
indication for its use is to determine the presence of
otherwise undetected metastatic disease.1 Other indica-
tions include monitoring response to induction chemother-
apy,2,3 postneoadjuvant chemoradiotherapy prognostica-
tion, and staging.4 – 6 We recently published our results on
an additional use of PET scan in surgically treated patients
with esophageal cancer, namely to identify early clinical
stage patients who might be at a higher risk for a poor
prognosis.7 In that study, we showed that using a maximal
standardized uptake values (SUV) of 4.5 (the median
SUVmax of the study group) in patients with adenocarci-
noma of the distal esophagus and gastroesophageal (GE)
junction segregated patients into high-risk and low-risk
groups, independent of clinical and pathologic stage.7 In
this current study, we investigated whether a SUVmax
greater or less than 4.5 could also stratify prognostically
patients with locally advanced adenocarcinoma and GE
junction adenocarcinoma who receive preoperative chemo-
radiotherapy.
METHODS
We reviewed the medical records of all patients
identified in a database maintained by the Thoracic Sur-
gery Service who underwent an esophagogastrectomy for
adenocarcinoma of the distal esophagus or gastroesopha-
geal junction (Siewert types 1 and 2) between January
1996 and September 2007. January 1996 was the date
when an institutional electronic medical record system was
initiated and therefore represents the date at which highly
reliable information became available. Patients were eli-
gible for inclusion in the study if they had histologically
proven adenocarcinoma of the distal esophagus and gas-
troesophageal junction, and if they underwent planned
preoperative treatment with chemoradiotherapy. The indi-
cation to receive preoperative therapy was clinical evi-
dence of locally advanced disease (American Joint Com-
mittee on Cancer stage II–IVa), confirmed by computed
tomography (CT), PET scan, or an endoscopic ultrasound
(EUS) T3 or N1 lesion. When gross full thickness involve-
ment of the esophageal wall was evident by CT, patients
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did not always undergo a confirmatory EUS. All patients
had a PET scan performed with an SUVmax reported before
the initiation of chemoradiotherapy. Using our previously
published cutoff, patients with an SUVmax 4.5 were
termed “low SUV,” and patients with an SUVmax 4.5
were termed “high SUV.” All patients must have survived
their perioperative course and received adequate follow-up
for survival analysis. The data collected included patient
demographics, PET scan data (including the primary tumor
SUV as well evidence of Fluorodeoxyglucose [FDG] avid
lymph nodes), CT scan evidence of adenopathy, EUS
assessment of primary tumor T and N stages (morphologic
assessment by endoscopist), and preoperative treatment
details (chemotherapy type, radiation dose, time from
completion of radiation to surgery). Additional data col-
lected included pathologic findings, nodal status, estimated
percent treatment response, pathologic complete response
(pCR, defined as no residual local or nodal disease), and
survival. All pathologic data were reviewed by a single
pathologist (LT). This review was performed after ap-
proval had been obtained from the Memorial Sloan-Ket-
tering Cancer Center Institutional Review Board and in
accordance with an assurance filed with and approved by
the Department of Health and Human Services.
Technique of 18FDG Whole-Body PET
Over 80% of the PET scans were done at two facil-
ities and were documented as performed on a dedicated
conventional full ring high resolution dedicated position
emission tomographs, with either the GE Advance (GEMS
Milwaukee, WI) or the CTI Biograph (CTI Knoxville,
TN). Patients were injected with pyrogen free F-18 FG
10 –15 mCi having been previously instructed to fast for at
least 6 hour before scanning. All images were recon-
structed using postemission transmission attenuation cor-
rected data sets. Region of interest analysis tools, shipped
with the scanners were used to calculate the maximal FDG
concentration within the primary tumor mass. Standard-
ized uptake values (SUVmax) were obtained by correcting
for the injected dose and the patient’s weight, again using
the standard software tools provided with the scanners. For
the purposes of this study, only 18FDG uptake in the
primary site of disease was analyzed. The remaining PET
scans were done at various other facilities, and the docu-
mented primary tumor SUVmax was recorded based on the
outside report without the possibility of further documen-
tation.
Estimation of Treatment Effect and Pathologic
Complete Response
The gross appearance of treated tumors varied from a
mucosal ulceration, to a fibrous scar, or a prominent mass
lesion in the case of a less than profound tumor regression.
Photographs of the gross specimen were taken on all cases.
The ulcerated or the scarred gross lesion at the gastro-
esophageal junction was blocked, sequentially and entirely
submitted for histopathological evaluation. When the tu-
mor was large in size (5.0 cm), only representative
sections of the tumor were examined microscopically. At
the microscopic level, a positive treatment-related effect
was observed as the malignant epithelium was destroyed
and replaced by reactive fibrosis or fibro-inflammation
within the mucosa or the gastroesophageal wall. Ulti-
mately, the pathologic response to treatment was deter-
mined by the amount of residual viable carcinoma that
remained in relation to areas of fibrosis or fibro-inflam-
mation within the gross lesion. The inverse of this number
was then expressed as a percentage (%). Thus, a 100%
treatment response indicated fibrosis or fibro-inflammation
within an entire gross lesion without microscopic evidence
of carcinoma, and a 0% treatment response represented an
entirely viable tumor in the absence of any fibrosis of
fibro-inflammation, respectively. Acellular mucin was re-
garded as a form of positive treatment response, not as a
residual/viable tumor. A pCR was assigned when there was
a 100% local treatment response.
Overall Outcome
The outcome evaluated was overall survival which
was calculated from the time of operation, and the date of
death was confirmed from the Social Security Death Index.
Follow-up was tracked through February 2008, constitut-
ing our censoring date for survival.
Statistical Analysis
Patient characteristics are described using tables for
categorical data, and medians and range for continuous
variables. Comparison of categorical variables was done
by 2 analysis and continuous variables by t test. Survival
analysis was done using the Kaplan-Meier method, with
comparison of survival using the log-rank test.
RESULTS
Clinical Data
During the study period, 995 esophagectomies for
cancer were performed, and 189 patients were appropriate
for this analysis. Five hundred and twenty-eight patients
were excluded because they did not receive chemoradia-
tion. Of the remaining 467 patients, patients were excluded
for the following reasons: 105 patients had squamous cell
carcinoma, 83 patients did not have a PET scan, 46
patients had a PET scan but no SUVmax recorded, 42
patients had a Siewert 3 tumor, and 2 patients did not have
survival data available. Of the 189 patients available for
analysis, 28 patients (14.8%) were in the low SUV group,
and 161 patients (85.2%) were in the high SUV group
(Figure 1). As shown in Table 1, there were no significant
differences in patient characteristics such as age and sex.
Although there was a trend toward a more advanced
clinical stage in the high SUVmax group, especially with
regards to EUS N1 disease (p  0.14) and PET adenopathy
(p  0.12), these differences were not statistically signif-
icant. The type of preoperative chemotherapy adminis-
tered, the dose of radiation, and the time from radiation
completion to surgery was the same in both groups.
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Survival of Low SUV and High SUVmax
Groups
As seen in Figure 2, the overall survival of the 2
patient groups was not significantly different (p  0.40).
At 3 years, 49.0% of the low SUV group was alive, and
57.9% of the high SUV group was alive.
Pathologic Findings of Low SUV and High
SUVmax Groups
There was a significant difference in the findings on
final pathologic examination between the two groups of
patients. As shown in Table 2, the low SUV group was less
likely to experience a pCR (p  0.02), had less evidence of
a treatment response (p  0.02), and was more likely to
have persistent node positive disease (p  0.03).
FIGURE 2. Overall survival based on SUVmax group.
995 Esophagectomies
467 received pre-operave chemo-radiaon
528 paents did not receive 
pre-operave chemo-radiaon
(Excluded Paents)
105 paents with squamous cell carcinoma
83 paents without PET scans
46 paents with PET scans but 
no SUVmax recorded
42 paents with Siewert 3 tumors
2 paents with no survival data
189 paents appropriate for further analysis
28 paents with an SUVmax <4.5                                       161 paents with an SUVmax ≥4.5
FIGURE 1. Reasons for the exclusions of patients from the analysis.







No. of patients 28 161
Age (mean) 62.7 61.4 0.50
Sex (female) 2 (7.1%) 23 (14.3%) 0.27
Clinical staging
CAT nodal disease 6 (21.4%) 41 (26.1%) 0.36
EUS T3 24/26 (92.3%) 107/120 (92.2%) 0.62
EUS N1 17/27 (63.0%) 89/121 (73.6%) 0.14




24 (85.7%) 142 (88.2%) 0.72
XRT dose (mean) 5040 cGy 5045 cGy 0.88
XRT completion
to surgery (mean)
59.3 d 60.8 d 0.89
Patient characteristics separated by SUV max group.
CAT, computed tomography; EUS, endoscopic ultrasound; PET, positron emission
tomography; XRT, radiotherapy; SUV PET, standardized uptake value.
Journal of Thoracic Oncology • Volume 4, Number 7, July 2009 Predictive Value of Initial PET-SUVmax in Patients
Copyright © 2009 by the International Association for the Study of Lung Cancer 877
DISCUSSION
The results from this study show that differences in
the pretreatment PET SUVmax do not predict overall sur-
vival in patients receiving combined modality therapy.
However, a high SUVmax is associated with a significantly
better response to induction therapy at the time of resec-
tion, as evidenced by a higher pCR rate, a greater esti-
mated treatment response, and a lower incidence of nodal
disease. Our hypothesis before initiating this study was
that patients in the low SUVmax group would have a better
survival than patients in the high SUVmax group. Support-
ing this expectation were several studies, including find-
ings in lung cancer8 –10 and esophageal cancer,7,11 which
have shown that a high SUVmax in patients undergoing
surgery is a predictor of a more advanced clinical and
pathologic stage and thereby a worse outcome. For in-
stance, our previous study on patients with esophageal
cancer who underwent surgery without preoperative che-
motherapy or chemo-radiotherapy showed that a low PET
SUVmax predicted a lower pathologic and clinical stage
and was associated with a better overall survival compared
with a high PET SUVmax.7 An additional expectation regard-
ing postchemoradiotherapy outcomes is that survival is pri-
marily associated with posttreatment nodal status and second-
arily with the pathologic treatment response.12 In our study,
however, the high SUVmax group had more favorable
postchemoradiotherapy pathologic characteristics, yet sur-
vival was no different than in the low SUVmax group. To
reconcile these discrepant findings, a reasonable interpreta-
tion of the results is that high SUVmax tumors have an
inherently worse outcome but are also more responsive to
chemoradiation, on balance resulting in a similar survival
between the two groups. Thus, while PET SUVmax ultimately
does not predict overall prognosis, it identifies which patients
are most likely to benefit from therapy.
PET scan is increasingly being used in patients un-
dergoing neoadjuvant therapy for esophageal cancer to
monitor their response to therapy.2,3 In general, the find-
ings from these studies have shown that patients who have
a larger change in SUVmax during treatment also show
evidence of a better treatment response and improved
survival.2,3 For example, In the MUNICON trial, Lordick
et al.2 showed that a 35% or more decrease in SUVmax after
2 weeks of chemotherapy was associated with a greater
histologic response as well as improved survival in pa-
tients with esophageal adenocarcinoma. Similar findings
have also been reported in other tumor types, including
lung cancer.13,14 Interestingly, in the MUNICON trial,2 an
additional noteworthy finding was that the median initial
SUVmax of the nonresponders was lower than in the re-
sponders (6.8 versus 8.3, respectively). This finding was
noted even though the trial excluded patients with a very
low initial SUVmax (cutoff not provided). Similar findings
that a high initial SUV was associated with a better
treatment response have also been reported by Wieder et
al.3 in esophageal squamous cell cancer. In this study, the
patients who were found to have a major histopathologic
response after chemoradiotherapy had a mean initial
SUVmax of 9.6, whereas those without a major response
had a an initial SUVmax of 3.5. Similar findings have been
noted by Dimtrakopoulou Strauss et al.15 in colorectal
cancer, Cremerius et al.16 in lymphoma, and by Lee et al.17
in lung cancer.
Underlying mechanisms, which might not only ex-
plain why high SUV tumors would have a worse initial
prognosis but also respond better to preoperative therapy,
are not well defined. Among proposed reasons is that a low
SUV might be associated with hypoxic tumors, that when
left untreated may be less aggressive, but paradoxically
may make the tumor more resistant to chemoradiothera-
py.18 Other possible mechanisms include higher tumor
proliferation indices in high SUV tumors19 which in turn
makes them more sensitive to preoperative therapy,17 in
vitro evidence of chemo resistance is associated with high
rates of membrane glucose transport,20 and disruption
of the membrane glucose transporter which is assoc-
iated with decreased FDG uptake and multiresistant
cell lines.21
The major limitation of this analysis is that it is
retrospective and as such the PET SUV results are subject
to both methodological and analytical variability. In addi-
tion, given the strong association between high SUVmax
and advanced clinical stage and the fact that our institution
treats patients with locally advanced disease with preop-
erative chemoradiotherapy, the number of patients in the
low SUV group was small. However, the strengths of this
study include the large number of patients studied over a
short time period, uniformity of induction therapy, and the
homogeneity of the patient population with respect to the
tumor type and location. In addition, a meticulous patho-
logic assessment of the resected tumor was possible in
every patient.
In conclusion, this study shows that in patients with
adenocarcinoma of the distal esophagus and GE junction
who undergo chemoradiotherapy before surgery, while a
low pretreatment SUV likely provides an inherent survival
advantage over a high SUV, this advantage is negated
because of the more dramatic response of high SUV
tumors to the preoperative chemoradiotherapy. This find-






Path CR 2 (7.1%) 41 (25.5%) 0.02
Depth of invasion (T)
T0 2 (7.1%) 41 (25.5%) 0.09
T1 4 (14.3%) 26 (16.2%)
T2 8 (28.6%) 42 (26.1%)
T3 14 (50%) 49 (30.4%)
T4 0 3 (1.9%)
Treatment effect (mean %) 62% 77% 0.02
Node positive 13 (46.4%) 41 (25.5%) 0.03
Correlation of pathologic characteristics with SUV max group.
CAT, computed tomography; EUS, endoscopic ultrasound; PET, positron emission
tomography; XRT, radiotherapy; SUV: PET, standardized uptake value.
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ing has implications for the design of future clinical trials,
and significant implications for a more appropriate selec-
tion of patients for preoperative chemoradiotherapy.
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